Kolon Pharmaceutical and Platbio merged

Reporter Kim Jisun / approved : 2023-03-30 09:48:35
  • -
  • +
  • 인쇄
This article is translated by AI company Flitto and Alhpa Biz neural machine translation technology
(사진= 코오롱제약 제공)

[Alpha Biz=(Chicago) Reporter Kim Jisun] Kolon Pharmaceutical will merge with Platbio, which has the capacity to develop new anti-cancer drugs, and start anew.

Kolon Pharmaceutical announced on the 29th that it had a merger ceremony with Platbio. The merger is scheduled to take place on June 1 by exchanging 2.38 shares of Kolon Pharmaceutical Co. per share of Platbio.

Kolon Pharmaceutical has been carrying out projects focused on improved new drugs and generic medicines. Platbio is a company that has developed anti-cancer drugs based on its ability to develop new drugs.

Since its establishment in 2018, Platbio has discovered more than 60 specific targets, including pancreatic cancer and ovarian cancer, and has continued to develop anticancer drugs.

The core technology of Platbio is in the homogenous model. It is a technology that accurately measures the efficacy and toxicity of new drugs by transplanting tumors directly into organs and greatly increases the success rate of new drugs.

It is developing candidate materials with the aim of developing treatments for various types of cancer, including pancreatic cancer, ovarian cancer and myeloid leukemia, and exporting them to the global market by 2025.

The two companies plan to establish a mid- to long-term growth plan after the merger and actively realize it. Starting with the development of major new drug pipelines, the company plans to expand technology transfer and joint research and development (R&D) with global pharmaceutical companies to global markets such as Korea and China. 

 

Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)

주요기사

[Exclusive] Samsung Electronics Passes NVIDIA’s HBM3E 12-High Qualification Test, Secures Supply Deal2025.09.19
Civic Groups File Complaint Against Baemin and Coupang Eats Over Alleged Misleading “One-Person Free Delivery” Promotions2025.09.19
KT Confirms Additional Victims in Unauthorized Micro-Payment Case, Faces Criticism Over Initial Response2025.09.19
KFTC Grants Conditional Approval for Joint Venture Between Shinsegae Group and Alibaba Group2025.09.19
Supreme Court Rules in Favor of NTS on U.S. Unregistered Patent Royalties2025.09.19
뉴스댓글 >

건강이 보이는 대표 K Medical 뉴스

HEADLINE

PHOTO

많이 본 기사